Can a Vaccine-Like shot retrain the immune system to stop diabetes?
NCT ID NCT03624062
First seen Feb 15, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This early-phase study tested a new treatment called IBC with MAS-1 adjuvant in 21 adults recently diagnosed with type 1 diabetes. The goal was to see if it is safe and can retrain the immune system to stop attacking the pancreas, potentially preserving natural insulin production. Participants received either the active treatment or a placebo, and researchers monitored side effects and immune system changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Colorado, Denver
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.